PubRank

Francesco M Marincola

Author PubWeight™ 312.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A human memory T cell subset with stem cell-like properties. Nat Med 2011 7.47
2 gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011 5.15
3 Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013 5.09
4 A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002 4.31
5 Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002 4.15
6 Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2005 3.23
7 Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014 3.21
8 Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009 3.02
9 Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008 2.94
10 Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012 2.88
11 The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013 2.86
12 The immune score as a new possible approach for the classification of cancer. J Transl Med 2012 2.79
13 Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007 2.69
14 MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010 2.57
15 MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010 2.48
16 BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013 2.36
17 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
18 Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005 2.24
19 Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002 2.21
20 Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007 2.10
21 Lost in Translation: Obstacles to Translational Medicine. J Transl Med 2004 2.03
22 The role of BRAF V600 mutation in melanoma. J Transl Med 2012 2.00
23 A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2011 1.99
24 Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002 1.96
25 Gene expression profiling of cutaneous wound healing. J Transl Med 2007 1.91
26 IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011 1.90
27 Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med 2003 1.88
28 MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med 2009 1.85
29 What's next in translational medicine? Clin Sci (Lond) 2007 1.85
30 In support of descriptive studies; relevance to translational research. J Transl Med 2007 1.82
31 Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009 1.81
32 A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008 1.77
33 Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002 1.74
34 Immunotherapy for melanoma: current status and perspectives. J Immunother 2010 1.72
35 The dual role of IL-10. Trends Immunol 2003 1.72
36 Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol 2006 1.69
37 The immunologic constant of rejection. Trends Immunol 2008 1.62
38 Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 2012 1.61
39 Obstacles and opportunities in translational research. Nat Med 2005 1.59
40 Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 2008 1.57
41 Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med 2010 1.57
42 Common cancer biomarkers. Cancer Res 2006 1.56
43 Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002 1.56
44 What have we learned from cancer immunotherapy in the last 3 years? J Transl Med 2014 1.52
45 Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol 2011 1.51
46 An immunologic portrait of cancer. J Transl Med 2011 1.50
47 Research translation: a new frontier for clinical laboratories. Clin Chem Lab Med 2006 1.48
48 Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol 2002 1.48
49 Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 2004 1.45
50 Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 2005 1.39
51 Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007 1.38
52 Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009 1.38
53 Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 2008 1.38
54 Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010 1.37
55 Natural T cell immunity against cancer. Clin Cancer Res 2003 1.36
56 Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 2009 1.34
57 Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med 2008 1.33
58 The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 2013 1.31
59 Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009 1.31
60 HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 2012 1.30
61 Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004 1.29
62 Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004 1.27
63 Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 2009 1.26
64 Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005 1.25
65 Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005 1.24
66 New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 2012 1.23
67 Clinical and translational medicine: Integrative and practical science. Clin Transl Med 2012 1.23
68 Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007 1.23
69 Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res 2008 1.22
70 Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med 2006 1.21
71 Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A 2011 1.20
72 Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2011 1.19
73 Deciphering the molecular machinery of stem cells: a look at the neoblast gene expression profile. Genome Biol 2007 1.18
74 Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. J Immunother 2002 1.17
75 Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med Genomics 2011 1.17
76 Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011 1.15
77 Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010 1.15
78 Effects of storage time and exogenous protease inhibitors on plasma protein levels. Am J Clin Pathol 2006 1.15
79 TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer 2014 1.15
80 Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother 2002 1.14
81 A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006 1.13
82 HLA class I and II genotype of the NCI-60 cell lines. J Transl Med 2005 1.11
83 Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion 2008 1.11
84 Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011 1.11
85 Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011 1.10
86 Supporting the advancement of science: open access publishing and the role of mandates. J Transl Med 2012 1.10
87 Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation. J Immunol 2012 1.10
88 Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 2011 1.09
89 Bottom up: a modular view of immunology. Immunity 2008 1.09
90 The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008 1.09
91 Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A 2009 1.08
92 miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med 2010 1.07
93 Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol 2002 1.07
94 miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 2013 1.07
95 Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002 1.07
96 Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One 2013 1.06
97 Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010 1.06
98 CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med 2007 1.06
99 The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 2009 1.06
100 Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 2011 1.06
101 A decade plus of translation: what do we understand? Clin Transl Med 2012 1.04
102 Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med 2012 1.04
103 Polarized monocyte response to cytokine stimulation. Genome Biol 2005 1.04
104 Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 2006 1.04
105 Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res 2011 1.04
106 Translational medicine--doing it backwards. J Transl Med 2010 1.03
107 Melanoma-restricted genes. J Transl Med 2004 1.03
108 Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med 2013 1.03
109 SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011 1.02
110 Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 2004 1.02
111 Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother 2009 1.01
112 Let-7 microRNAs are developmentally regulated in circulating human erythroid cells. J Transl Med 2009 1.01
113 Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. Exp Hematol 2005 1.01
114 Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope. J Immunol 2007 1.01
115 Active-specific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol 2003 1.00
116 Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother 2011 0.99
117 A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings. J Transl Med 2003 0.99
118 Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer 2013 0.98
119 Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011 0.98
120 How scientists use social media to communicate their research. J Transl Med 2011 0.98
121 Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics 2009 0.98
122 Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med 2005 0.98
123 Cancer vaccines: pessimism in check. Nat Med 2004 0.97
124 Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 2008 0.97
125 Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006 0.96
126 Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med 2010 0.96
127 Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest 2015 0.96
128 Gene profiling of immune responses against tumors. Curr Opin Immunol 2005 0.95
129 Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther 2005 0.95
130 A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 2004 0.95
131 Translational Medicine is developing in China: a new venue for collaboration. J Transl Med 2011 0.95
132 The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics 2012 0.95
133 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med 2013 0.95
134 Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J Transl Med 2005 0.95
135 Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med 2009 0.95
136 Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013 0.94
137 Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother 2002 0.94
138 Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother 2011 0.93
139 HLA associations with nasopharyngeal carcinoma. Curr Mol Med 2009 0.93
140 Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010 0.93
141 New HLA-A, -B, and -C locus-specific primers for PCR amplification from cDNA: application in clinical immunology. J Immunol Methods 2003 0.93
142 Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs 2009 0.92
143 MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts. Trends Mol Med 2006 0.91
144 Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion. J Transl Med 2006 0.91
145 Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002 0.91
146 Evaluation of normalization methods for two-channel microRNA microarrays. J Transl Med 2010 0.90
147 TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness. Cancer Res 2013 0.89
148 The perception of nanotechnology and nanomedicine: a worldwide social media study. Nanomedicine (Lond) 2014 0.89
149 The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele. Transfusion 2003 0.89
150 Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother 2014 0.89
151 Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med 2002 0.88
152 Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. Eur J Immunol 2010 0.88
153 Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic hybridization results. J Transl Med 2006 0.88
154 The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res 2005 0.88
155 High-dimensional analysis of the aging immune system: verification of age-associated differences in immune signaling responses in healthy donors. J Transl Med 2014 0.87
156 Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. Clin Cancer Res 2014 0.87
157 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. J Transl Med 2011 0.87
158 Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res 2004 0.87
159 RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management. Blood 2010 0.87
160 Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons? J Transl Med 2011 0.87
161 Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res 2007 0.87
162 A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma. Int J Cancer 2003 0.87
163 Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response. Cancer Immunol Immunother 2008 0.86
164 IRF5 gene polymorphisms in melanoma. J Transl Med 2012 0.86
165 Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue. Biotechniques 2005 0.86
166 A genetic inference on cancer immune responsiveness. Oncoimmunology 2012 0.86
167 Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS. Int Immunol 2008 0.86
168 GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med 2008 0.86
169 Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. J Transl Med 2007 0.86
170 Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit Rev Immunol 2007 0.86
171 Expanding the perspective of translational medicine: the value of observational data. J Transl Med 2012 0.86
172 Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer 2011 0.85
173 Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling. Mol Ther 2012 0.85
174 Combination therapy: the next opportunity and challenge of medicine. J Transl Med 2011 0.85
175 A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities. J Cell Mol Med 2009 0.85
176 Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol 2011 0.85
177 Cytokine polymorphism and its possible impact on cancer. Immunol Res 2004 0.85
178 Gene expression profiling of anticancer immune responses. Curr Opin Mol Ther 2004 0.85
179 Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells. Transfusion 2008 0.85
180 Spontaneous and treatment-induced cancer rejection in humans. Expert Opin Biol Ther 2008 0.85
181 Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments. J Transl Med 2011 0.85
182 Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays. Cytokine 2004 0.85
183 Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model. J Transl Med 2009 0.85
184 Racial differences in B cell receptor signaling pathway activation. J Transl Med 2012 0.84
185 The role of quantitative PCR for the immune monitoring of cancer patients. Expert Opin Biol Ther 2002 0.84
186 Common pathways to tumor rejection. Ann N Y Acad Sci 2013 0.83
187 Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol 2015 0.83
188 Characterization of human melanoma cell lines and melanocytes by proteome analysis. Cell Cycle 2011 0.83
189 Migration deficit in monocyte-macrophages in human ovarian cancer. Cancer Immunol Immunother 2007 0.83
190 Understanding the response to immunotherapy in humans. Springer Semin Immunopathol 2005 0.83
191 Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett 2009 0.83
192 Immunotherapy of melanoma: the good news, the bad ones and what to do next. Semin Cancer Biol 2003 0.83
193 The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2. Cancer Immunol Immunother 2006 0.82
194 AAAS joins the Translational Medicine family. J Transl Med 2009 0.82
195 Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opin Biol Ther 2014 0.82
196 A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One 2012 0.82
197 CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat 2010 0.82
198 New take on comparative immunology: relevance to immunotherapy. Immunotherapy 2009 0.82
199 The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med 2011 0.82
200 Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells. Proteomics 2011 0.81
201 DNA array-based gene profiling in tumor immunology. Clin Cancer Res 2004 0.81
202 Pyrosequencing trade mark : A one-step method for high resolution HLA typing. J Transl Med 2003 0.81
203 Quantitative real-time PCR in cancer research. Arch Immunol Ther Exp (Warsz) 2003 0.81
204 Impact of carbon nanotubes and graphene on immune cells. J Transl Med 2014 0.81
205 Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest 2014 0.81
206 Gene profiling for the prediction of tumor response to treatment: the case of immunotherapy. Adv Exp Med Biol 2007 0.80
207 Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display. Cancer Res 2007 0.80
208 A global approach to tumor immunology. Cell Mol Immunol 2004 0.80
209 Advancing cancer biotherapy with proteomics. J Immunother 2005 0.80
210 Widespread and ample peptide overlapping between HCV and Homo sapiens proteomes. Peptides 2007 0.80
211 Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med 2004 0.80
212 The modulation of hepatitis C virus 1a replication by PKR is dependent on NF-kB mediated interferon beta response in Huh7.5.1 cells. Virology 2013 0.80
213 Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. Cancer Immunol Immunother 2006 0.80
214 The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2008-09. J Transl Med 2010 0.80
215 Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients. Am J Pathol 2013 0.80
216 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
217 Biotechnology entrepreneurship--where no research has gone before. J Transl Med 2010 0.79
218 Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy. Cancer Res 2008 0.79
219 Conference Scene: Immunotherapy reaches new milestones in cancer eradication. Immunotherapy 2011 0.79
220 Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. Int J Cancer 2010 0.79
221 Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178. Int J Cancer 2003 0.79
222 Lean oncology: a new model for oncologists. J Transl Med 2012 0.79
223 How to analyze ex vivo T-cell responses in cancer patients. In Vivo 2002 0.79
224 Quality assessment of cellular therapies: the emerging role of molecular assays. Korean J Hematol 2010 0.79
225 Bridging the divide between science and journalism. J Transl Med 2010 0.79
226 The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM). Clin Transl Med 2012 0.79
227 Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells. Immunology 2014 0.79
228 Global transcriptional analysis for biomarker discovery and validation in cellular therapies. Mol Diagn Ther 2009 0.79
229 Stem cells in melanoma development. Cancer Lett 2008 0.78
230 A global resource to translational medicine: the International Park of Translational Medicine and BioMedicine (IPTBM). J Transl Med 2013 0.78
231 The transcription factor BACH2 promotes tumor immunosuppression. J Clin Invest 2016 0.78
232 Functional characterization of CTL against gp100 altered peptide ligands. Cancer Immunol Immunother 2003 0.78
233 Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine. Clin Transl Med 2012 0.78
234 Mechanism of immune response during immunotherapy. Yonsei Med J 2004 0.78
235 The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. Clin Cancer Res 2007 0.78
236 Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M. Cancer Immunol Immunother 2004 0.78
237 Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. Hum Gene Ther Methods 2012 0.77
238 Complementary techniques: RNA amplification for gene profiling analysis. Adv Exp Med Biol 2007 0.77
239 Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells. J Immunother 2002 0.77
240 Transcriptional analysis of tumor-specific T-cell responses in cancer patients. Crit Rev Immunol 2002 0.77
241 Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. Eur J Immunol 2015 0.77
242 Autologous tumor rejection in humans: trimming the myths. Immunol Invest 2006 0.77
243 Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. Immunotherapy 2009 0.77
244 Analysis of vaccine-induced T cells in humans with cancer. Adv Exp Med Biol 2010 0.77
245 Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus. J Transl Med 2015 0.76
246 Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother 2012 0.76
247 Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy. J Transl Med 2014 0.76
248 Tumor microenvironment and the immune response. Surg Oncol Clin N Am 2007 0.76
249 The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value. Immunol Res 2015 0.76
250 Increased effector-target cell conjugate formation due to HLA restricted specific antigen recognition. Immunol Res 2009 0.76
251 International meeting "Immunotherapy of cancer: challenges and needs". Cancer Immunol Immunother 2006 0.76
252 Bacteria-related spontaneous and therapeutic remission of human malignancies. In Vivo 2002 0.76
253 Inter-donor variation in cell subset specific immune signaling responses in healthy individuals. Am J Clin Exp Immunol 2012 0.76
254 Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood 2012 0.76
255 Applying the uncertainty principle to immunology. Immunotherapy 2011 0.75
256 Microarray analysis for a comprehensive immunological-status evaluation during cancer vaccine immune monitoring. J Biomed Biotechnol 2011 0.75
257 Cancer vaccines at an inflexion point: what next? J Transl Med 2011 0.75
258 Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol 2012 0.75
259 "Sequencing-grade" screening for BRCA1 variants by oligo-arrays. J Transl Med 2008 0.75
260 Turning laboratory findings into therapy: a marathon goal that has to be reached. Pol Arch Med Wewn 2009 0.75
261 The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2007-08. J Transl Med 2009 0.75
262 Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? J Proteome Res 2011 0.75
263 Methods to measure vaccine immunity. Expert Rev Vaccines 2010 0.75
264 Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology. PLoS One 2010 0.75
265 Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med 2011 0.75
266 IFN-conditioned dendritic cells for the therapy of melanoma: what is missing? J Immunother 2011 0.75
267 Vaccination with T cell-defined antigens. Expert Opin Biol Ther 2004 0.75
268 Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim Biophys Acta 2003 0.75
269 Overview of melanoma vaccines and promising approaches. Curr Oncol Rep 2004 0.75
270 Melanoma: from research to treatment. J Skin Cancer 2012 0.75
271 Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield? Tumori 2003 0.75
272 The challenge of implementing high-throughput technologies in clinical trials. Pharmacogenomics 2005 0.75